MDT

95.86

-0.14%↓

VEEV

289.87

+1.52%↑

A

145.91

+2.06%↑

HQY

95.86

+2.98%↑

TLRY

1.48

-5.73%↓

MDT

95.86

-0.14%↓

VEEV

289.87

+1.52%↑

A

145.91

+2.06%↑

HQY

95.86

+2.98%↑

TLRY

1.48

-5.73%↓

MDT

95.86

-0.14%↓

VEEV

289.87

+1.52%↑

A

145.91

+2.06%↑

HQY

95.86

+2.98%↑

TLRY

1.48

-5.73%↓

MDT

95.86

-0.14%↓

VEEV

289.87

+1.52%↑

A

145.91

+2.06%↑

HQY

95.86

+2.98%↑

TLRY

1.48

-5.73%↓

MDT

95.86

-0.14%↓

VEEV

289.87

+1.52%↑

A

145.91

+2.06%↑

HQY

95.86

+2.98%↑

TLRY

1.48

-5.73%↓

Search

Organon & Co

Cerrado

SectorSanidad

9.04 -2.27

Resumen

Variación precio

24h

Actual

Mínimo

8.99

Máximo

9.29

Métricas clave

By Trading Economics

Ingresos

-174M

-87M

Ventas

81M

1.6B

P/B

Media del Sector

3.435

37.461

BPA

1

Rentabilidad por dividendo

9.27

Margen de beneficios

-5.443

Empleados

10,000

EBITDA

124M

449M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 Meses

+73.16% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

9.27%

2.33%

Próximas Ganancias

30 oct 2025

Fecha Próximo Dividendo

11 dic 2025

Próxima Fecha de Ex Dividendo

12 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-101M

2.4B

Apertura anterior

11.31

Cierre anterior

9.04

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

56 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Organon & Co Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

21 oct 2025, 23:55 UTC

Acciones populares

Stocks to Watch: DraftKings, Texas Instruments, Intuitive Surgical, Pegasystems

21 oct 2025, 23:49 UTC

Ganancias

Texas Instruments Warns of Slower Semiconductor Industry Recovery -- Update

21 oct 2025, 21:40 UTC

Ganancias

Waste Connections 3Q Revenue Rises

21 oct 2025, 21:14 UTC

Ganancias
Principales Movimientos del Mercado

Intuitive Surgical 3Q Profit, Sales Jump, Sees Higher da Vinci Procedure Growth -- Update

21 oct 2025, 21:05 UTC

Adquisiciones, fusiones, absorciones

GE Vernova to Acquire Full Stake in Prolec GE Joint Venture

21 oct 2025, 20:57 UTC

Adquisiciones, fusiones, absorciones

DraftKings to Launch Prediction Markets Platform

21 oct 2025, 20:38 UTC

Ganancias

Intuitive Surgical 3Q Profit, Sales Jump, Sees Higher da Vinci Procedure Growth

21 oct 2025, 20:35 UTC

Ganancias

Capital One 3Q Sales, Profit Jump

21 oct 2025, 20:32 UTC

Ganancias

Texas Instruments 3Q Revenue Up on Growth Across End Markets

21 oct 2025, 23:44 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

21 oct 2025, 23:44 UTC

Charlas de Mercado

Nikkei May Rise on Weaker Yen, Hopes for Takaichi's Econ Steps -- Market Talk

21 oct 2025, 23:39 UTC

Charlas de Mercado

Gold Consolidates; May Undergo Further Technical Correction -- Market Talk

21 oct 2025, 23:36 UTC

Charlas de Mercado

BHP Has Hidden Leverage to Gold's Rush -- Market Talk

21 oct 2025, 22:55 UTC

Adquisiciones, fusiones, absorciones

Scentre Says This Forms Part of Capital Management Strategy

21 oct 2025, 22:55 UTC

Adquisiciones, fusiones, absorciones

Scentre: Continues to Evaluate Strategic Opportunities Including New JV Partners

21 oct 2025, 22:54 UTC

Adquisiciones, fusiones, absorciones

Scentre Notes Media Report on Possible Sale of Stake in Westfield Chermside to Dexus Fund

21 oct 2025, 21:09 UTC

Charlas de Mercado
Ganancias

Netflix Creators Have Started Using AI in Production -- Market Talk

21 oct 2025, 20:58 UTC

Charlas de Mercado
Ganancias

Netflix Aims to Build on 'KPop Demon Hunters' Mania -- Market Talk

21 oct 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

21 oct 2025, 20:50 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Financial Services Roundup: Market Talk

21 oct 2025, 20:43 UTC

Ganancias

Netflix Stock Drops After Earnings Miss Estimates -- Barrons.com

21 oct 2025, 20:41 UTC

Ganancias

Dow Industrials Hit Record, Boosted by Strong Earnings -- WSJ

21 oct 2025, 20:33 UTC

Adquisiciones, fusiones, absorciones

GE Vernova: Deal Accelerates Growth for Electrification Segment >GEV

21 oct 2025, 20:33 UTC

Adquisiciones, fusiones, absorciones

GE Vernova Acquiring Remaining 50% Stake of JV From Xignux >GEV

21 oct 2025, 20:32 UTC

Adquisiciones, fusiones, absorciones

GE Vernova: Prolec GE Expects Low Double-Digit Rev Growth in Coming Years >GEV

21 oct 2025, 20:32 UTC

Adquisiciones, fusiones, absorciones

GE Vernova: Prolec GE Expects $3B in Rev at 25% Adj EBITDA Margin in 2025 >GEV

21 oct 2025, 20:32 UTC

Adquisiciones, fusiones, absorciones

GE Vernova: $5.275B Purchase Price at Closing, Expected to Be Funded Equally With Cash & Debt >GEV

21 oct 2025, 20:32 UTC

Adquisiciones, fusiones, absorciones

GE Vernova Will Acquire Remaining 50% Stake of Prolec GE >GEV

21 oct 2025, 20:31 UTC

Adquisiciones, fusiones, absorciones

GE Vernova To Fully Acquire Prolec GE Joint Venture >GEV

21 oct 2025, 20:29 UTC

Ganancias

Northrop Stock Tumbles on Sales Disappointment. When Good Isn't Good Enough. -- Barrons.com

Comparación entre iguales

Cambio de precio

Organon & Co previsión

Precio Objetivo

By TipRanks

73.16% repunte

Estimación a 12 Meses

Media 16 USD  73.16%

Máximo 18 USD

Mínimo 14 USD

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Organon & Co Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

2 ratings

1

Comprar

0

Mantener

1

Vender

Puntuación técnica

By Trading Central

8.53 / 9.18Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

No Evidence

Sentimiento

By Acuity

56 / 371 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Organon & Co

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.
help-icon Live chat